FDA Approved Medical Products for:

Hemophilia A, congenital

The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products.

Generic Name antihemophilic factor (recombinant), Fc fusion protein
Trade Name
(Manufacturer Name)
Eloctate
(Biogen Idec Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Generic Name Antihemophilic factor (recombinant)
Trade Name
(Manufacturer Name)
Kogenate FS
(Bayer Corporation)
Indication
The FDA has approved this product to be used in this manner.
Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease)
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Coagulation Factor VIIa (Recombinant)
Trade Name
(Manufacturer Name)
NovoSeven® RT
(Novo Nordisk, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of bleeding episodes in patients with Factor VII Deficiency. Treatment and peri-operative management of Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.
More Information about this product Drug Information Portal

Generic Name Antihemophilic factor (recombinant)
Trade Name
(Manufacturer Name)
ReFacto®
(Wyeth Pharmaceuticals, Inc.)
Indication
The FDA has approved this product to be used in this manner.
For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
More Information about this product Drug Information Portal
Medline Plus Health Information

Generic Name Desmopressin acetate
Trade Name
(Manufacturer Name)
Stimate®
(CSL Behring)
Indication
The FDA has approved this product to be used in this manner.
Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.
More Information about this product Drug Information Portal